ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordersA gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta Share XASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordershttps://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/
CRISPR trials yield encouraging data in blood disordersData on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta Share XCRISPR trials yield encouraging data in blood disordershttps://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/
FDA gives go-ahead for CRISPR-based sickle cell disease trialDevelopment of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can Share XFDA gives go-ahead for CRISPR-based sickle cell disease trialhttps://pharmaphorum.com/news/fda-gives-go-ahead-for-crispr-based-sickle-cell-disease-trial/
